Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Cancer

• Publication date

  2010-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.25077PMID 19960433
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erratum to: Endometrial Cancer

  2017cited by this paper
• Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.

  2009cited by this paper
• Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.

  2008cited by this paper
• Novel molecular profiles of endometrial cancer-new light through old windows.

  2008cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• Molecular therapy and prevention of liver diseases

  2008cited by this paper
• An introduction to molecular targeted therapy of cancer.

  2008cited by this paper
• The role of DNA ploidy in postoperative management of stage I endometrial cancer.

  2008cited by this paper
• Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis

  2008cited by this paper
• Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy

  2008cited by this paper
• Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer.

  2007cited by this paper
• Levels of circulating cell-free serum DNA in benign and malignant breast lesions.

  2007cited by this paper
• Molecular carcinogenesis of endometrial cancer.

  2007cited by this paper
• Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium.

  2007cited by this paper
• Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.

  2007cited by this paper
• Prediction of breast tumor progression by integrity of free circulating DNA in serum.

  2006cited by this paper
• Autoantibody biomarkers in the detection of cancer.

  2006cited by this paper
• Sequencing analysis of BRAF mutations in human cancers.

  2006cited by this paper
• Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.

  2006cited by this paper
• Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

  2006cited by this paper
• Diagnostic developments involving cell-free (circulating) nucleic acids.

  2006cited by this paper
• TP53 overexpression in recurrent endometrial carcinoma.

  2006cited by this paper
• Involvement of the ras genes in female genital tract cancer.

  2005cited by this paper
• Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease

  2005cited by this paper
• Endometrial cancer.

  2005cited by this paper
• Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas

  2005cited by this paper
• Circulation DNA: biological implications for cancer metastasis and immunology.

  2005cited by this paper
• Molecular Genetics of Uterine Malignancies

  2004influential reference
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cited by this paper
• BCL-2 and P53 expression in endometrial carcinoma.

  2004cited by this paper
• Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification

  2004influential reference
• p53 autoantibodies can be indicative of the development of breast cancer relapse.

  2003cited by this paper
• Increased plasma DNA integrity in cancer patients.

  2003cited by this paper
• MOLECULAR ASSESSMENT OF DEPTH OF MYOMETRIAL INVASION IN STAGE I ENDOMETRIAL CANCER: A MODEL BASED ON K-RAS MUTATION ANALYSIS

  2003cited by this paper
• Lack of Apoptosis in PanIN-1 and PanIN-2 Lesions Associated with Pancreatic Ductal Adenocarcinoma Is Not Dependent on K-ras Status

  2003cited by this paper
• p53 overexpression as a prognostic indicator in endometrial carcinoma.

  2003cited by this paper
• World Cancer Report

  2003cited by this paper
• Circulating DNA: a new diagnostic gold mine?

  2002cited by this paper
• P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis

  2002cited by this paper
• Molecular pathogenesis and prognostic factors in endometrial carcinoma

  2002cited by this paper
• Detection of human papillomavirus DNA, serum p53, and p53 antibodies in patients with cervical cancer.

  2002cited by this paper
• Current molecular aspects of the carcinogenesis of the uterine endometrium

  2001cited by this paper
• Serum Anti-p53 Antibodies in Uterine and Ovarian Cancer: Association with DNA Sequence Copy Number Abnormalities

  2001cited by this paper
• Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.

  2001cited by this paper
• Patterns of immunohistochemical staining for p53 expression in hyperplastic endometrium and adenocarcinoma.

  2001cited by this paper
• Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma

  2001cited by this paper
• The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma

  2000influential reference
• Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

  2000cited by this paper
• Serum evaluation of P53 protein in patients with gynaecological cancer.

  2000cited by this paper
• p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.

  2000cited by this paper
• p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Human Risk Assessment

  2000cited by this paper
• Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass

  2000cited by this paper
• Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.

  1999cited by this paper
• K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

  1999cited by this paper
• Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: a comparative study.

  1997cited by this paper
• Detection of tumour DNA in serum of colorectal cancer patients.

  1997cited by this paper
• K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.

  1996cited by this paper
• Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer

  1996cited by this paper
• Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.

  1996cited by this paper
• Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer

  1994cited by this paper
• Studies on ras oncogene activation in endometrial carcinoma

  1993cited by this paper
• Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.

  1992influential reference
• K-ras activation in premalignant and malignant epithelial lesions of the human uterus.

  1991cited by this paper
• Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

  1982cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper

• Management of Advanced Stage Endometrial Cancer With Non-Measurable Disease After Surgery

  2025cites this paper
• Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer

  2025cites this paper
• Advancements in Minimally Invasive Techniques and Biomarkers for the Early Detection of Endometrial Cancer: A Comprehensive Review of Novel Diagnostic Approaches and Clinical Implications

  2024cites this paper
• Targeting KRAS in gynecological malignancies

  2024cites this paper
• Advances and challenges in the use of liquid biopsy in gynaecological oncology

  2024cites this paper
• Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

  2024cites this paper
• Cell‐free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls

  2024cites this paper
• Prognosis of Stage I Endometrial Cancer According to the FIGO 2023 Classification Taking into Account Molecular Changes

  2024cites this paper
• Clinical application of liquid biopsy in endometrial carcinoma

  2023influential citation
• Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows

  2023cites this paper
• The role of ctDNA in endometrial cancer: A tool for risk stratification and disease monitoring.

  2023cites this paper
• It is time to implement molecular classification in endometrial cancer

  2023cites this paper
• Noninvasive detection of microsatellite instability in patients with endometrial cancer

  2023cites this paper
• Liquid biopsy in female genital tract (ovarian cancer, endometrial tumor, and cervical tumor)

  2022cites this paper
• Future Challenges and Perspectives of Endometrial Cytology

  2022cites this paper
• The Future Direction in Endometrial Oncology through the Liquid Biopsy

  2022cites this paper
• Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment

  2022cites this paper
• Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma

  2022cites this paper
• Improving the Management of Endometrial Cancer Patients through the Use of Liquid Biopsy Analyses: A Case Report

  2022cites this paper
• Current and Emerging Prognostic Biomarkers in Endometrial Cancer

  2022influential citation
• Cytology for the diagnosis of endometrial cancer in symptomatic women

  2021cites this paper
• The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application

  2021cites this paper
• Liquid biopsy in endometrial cancer

  2020cites this paper
• Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers

  2020cites this paper
• Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?

  2020cites this paper
• Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer

  2020cites this paper
• Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer

  2020cites this paper
• Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof‐of‐concept study

  2020cites this paper
• Endometrial cancer patients have high affinity antibodies for estrogen metabolite–receptor aggregate: A potential biomarker for EC

  2020influential citation
• Low molecular weight serum cell-free DNA concentration is associated with clinicopathologic indices of poor prognosis in women with uterine cancer

  2020cites this paper
• Endometrial cancer: a genetic point of view

  2020cites this paper
• [Circulating tumor DNA assessment for gynaecological cancers management].

  2019cites this paper
• Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer

  2019influential citation
• A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR

  2019cites this paper
• Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer

  2019influential citation
• Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology

  2018influential citation
• Liquid biopsy for cancer screening, patient stratification and monitoring

  2018cites this paper
• Gynecologic Cancers: Molecular Updates 2018.

  2018cites this paper
• Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies

  2018cites this paper
• High Expression of Ubiquitin C-terminal Hydrolase L1 Is Associated With Poor Prognosis in Endometrial Cancer Patients

  2018cites this paper
• Biomarkers of Endometrial Cancer

  2017cites this paper
• Circulating cell-free DNA content as blood based biomarker in endometrial cancer

  2017cites this paper
• Quality of life in long-term survivors of early stage endometrial cancer.

  2017cites this paper
• Endometrial Cancer Biomarkers in Circulation

  2017cites this paper
• Suspended in Blood and Circulating Within, Cell Free (cf) DNA Connects with a Vast Range of Adverse Human Health Conditions Including Cancer: A Review.

  2015cites this paper
• The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients.

  2014cites this paper
• Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

  2014cites this paper
• Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy.

  2014cites this paper
• Tumor-Associated Circulating MicroRNAs as Biomarkers of Cancer

  2014cites this paper
• Polymorphism of p53 gene codon 72 in endometrial cancer: correlation with tumor grade and histological type.

  2014cites this paper
• The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients

  2013cites this paper
• Endometrial cancer: molecular and therapeutic aspects.

  2013cites this paper
• Quantification of serum HBXAP DNA in lung cancer patients by quantitative fluorescent polymerase chain reaction

  2013cites this paper
• Genomic and genetic alterations in endometrial adenocarcinoma

  2013cites this paper
• Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients

  2013cites this paper
• Genomic Alterations in Experimental Endometrial Adenocarcinoma

  2012cites this paper
• Circulating DNA markers of gastro-intestinal cancers

  2012influential citation
• Detection of cancer‐specific epigenomic changes in biofluids: Powerful tools in biomarker discovery and application

  2012cites this paper
• The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer.

  2012cites this paper
• Modified PNA-PCR method

  2012cites this paper
• Role of Circulating Free Alu DNA in Endometrial Cancer

  2012cites this paper
• Improved blood tests for cancer screening: general or specific?

  2011cites this paper
• Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.

  2011cites this paper
• Optical biosensors to analyze novel biomarkers in oncology

  2011cites this paper
• Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids.

  2011cites this paper
• Quanti cation of plasma hTERT

  2011cites this paper
• Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.

  2011cites this paper
• Circulating tumour markers can define patients with normal colons, benign polyps, and cancers

  2011cites this paper
• Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing

  2011cites this paper
• Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction.

  2011cites this paper
• Circulating tumour markers can define patients with normal colons, benign polyps and cancers

  2011cites this paper
• Biomarkers as prognostic factors in endometrial cancer.

  2010cites this paper
• Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

  2010cites this paper